📊 WGSWW Key Takeaways
Is GeneDx Holdings Corp. (WGSWW) a Good Investment?
GeneDx demonstrates strong fundamental growth with 40% YoY revenue increase and exceptional 69.7% gross margins, indicating robust unit economics in its diagnostic services business. Despite current operating losses, the company maintains positive free cash flow of $14.3M, substantial cash reserves of $105M, and a fortress balance sheet (0.18x D/E), providing financial runway to achieve profitability as it scales. Improving losses (59.8% YoY improvement in net income) suggest operational leverage is beginning to materialize.
Why Buy GeneDx Holdings Corp. Stock? WGSWW Key Strengths
- Exceptional revenue growth of 40% YoY demonstrates strong market demand and scalability
- High gross margin of 69.7% indicates strong pricing power and unit economics in diagnostic services
- Positive free cash flow of $14.3M despite GAAP losses shows sustainable cash generation
- Strong balance sheet with $105M cash, low leverage (0.18x D/E), and 2.46x current ratio provide financial flexibility
- Improving profitability trajectory with net income up 59.8% YoY and EPS improving 62.4% YoY
WGSWW Stock Risks: GeneDx Holdings Corp. Investment Risks
- Operating losses of -$13.1M (-3.1% margin) despite strong growth indicates high operating expenses relative to revenue generation
- Negative interest coverage ratio (-9.4x) reflects inability to cover debt service from operating income
- Path to profitability timeline and sustainability unclear; operating expense ratio of 72.8% of revenue must compress significantly
- Cash burn continues on GAAP basis (-$21M net loss) despite positive FCF, indicating reliance on non-cash items for FCF conversion
- Unproven ability to achieve operating leverage; may face margin compression if growth decelerates without cost control
Key Metrics to Watch
- Operating margin trajectory and timeline to positive operating income
- Operating expense ratio as percentage of revenue; need to see compression below 65% for sustainability
- Free cash flow conversion and FCF margin sustainability (currently 3.3%)
- Revenue growth rate sustainability beyond current 40% YoY pace
- Cash runway and burn rate; cash consumption relative to positive FCF generation
GeneDx Holdings Corp. (WGSWW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.3% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.46x current ratio provides a solid financial cushion.
WGSWW Profit Margin, ROE & Profitability Analysis
WGSWW vs Services Sector: How GeneDx Holdings Corp. Compares
How GeneDx Holdings Corp. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GeneDx Holdings Corp. Stock Overvalued? WGSWW Valuation Analysis 2026
Based on fundamental analysis, GeneDx Holdings Corp. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GeneDx Holdings Corp. Balance Sheet: WGSWW Debt, Cash & Liquidity
WGSWW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GeneDx Holdings Corp.'s revenue has grown significantly by 101% over the 5-year period, indicating strong business expansion. The most recent EPS of $-7.23 indicates the company is currently unprofitable.
WGSWW Revenue Growth, EPS Growth & YoY Performance
WGSWW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $76.9M | -$3.4M | $-0.12 |
| Q2 2025 | $70.5M | $4.3M | $0.14 |
| Q1 2025 | $62.4M | -$6.5M | $-0.23 |
| Q3 2024 | $53.3M | -$8.3M | $-0.31 |
| Q2 2024 | $48.7M | -$29.2M | $-1.10 |
| Q1 2024 | $43.1M | -$20.2M | $-0.78 |
| Q3 2023 | $53.3M | -$42.3M | $-1.64 |
| Q2 2023 | $36.2M | -$46.7M | $-1.84 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GeneDx Holdings Corp. Dividends, Buybacks & Capital Allocation
WGSWW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GeneDx Holdings Corp. (CIK: 0001818331)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 30, 2026 | 4 | xslF345X06/form4-03302026_090356.xml | View → |
| Mar 30, 2026 | 4 | xslF345X06/form4-03302026_080325.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_100354.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_100356.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/form4-03112026_080344.xml | View → |
❓ Frequently Asked Questions about WGSWW
What is the AI rating for WGSWW?
GeneDx Holdings Corp. (WGSWW) has an AI rating of BUY with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are WGSWW's key strengths?
Claude: Exceptional revenue growth of 40% YoY demonstrates strong market demand and scalability. High gross margin of 69.7% indicates strong pricing power and unit economics in diagnostic services.
What are the risks of investing in WGSWW?
Claude: Operating losses of -$13.1M (-3.1% margin) despite strong growth indicates high operating expenses relative to revenue generation. Negative interest coverage ratio (-9.4x) reflects inability to cover debt service from operating income.
What is WGSWW's revenue and growth?
GeneDx Holdings Corp. reported revenue of $427.5M.
Does WGSWW pay dividends?
GeneDx Holdings Corp. does not currently pay dividends.
Where can I find WGSWW SEC filings?
Official SEC filings for GeneDx Holdings Corp. (CIK: 0001818331) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is WGSWW's EPS?
GeneDx Holdings Corp. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is WGSWW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GeneDx Holdings Corp. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is WGSWW stock overvalued or undervalued?
Valuation metrics for WGSWW: ROE of -6.8% (sector avg: 16%), net margin of -4.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy WGSWW stock in 2026?
Our dual AI analysis gives GeneDx Holdings Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is WGSWW's free cash flow?
GeneDx Holdings Corp.'s operating cash flow is $33.3M, with capital expenditures of $19.0M. FCF margin is 3.3%.
How does WGSWW compare to other Services stocks?
Vs Services sector averages: Net margin -4.9% (avg: 10%), ROE -6.8% (avg: 16%), current ratio 2.46 (avg: 1.5).